Sign Up
OverviewAPI
Basilea Pharmaceutica Ltd reports strong 2023 full-year results, with revenue of CHF 157.6 million. The company aims to enter into a commercial partnership for the US for its antibiotic ceftobiprole. Basilea's financial summary shows a net profit of CHF 10.5 million and a positive cash flow of CHF 14.2 million.

Ask a question